



## Capecitabine Therapy and *DPYD* Genotype

Laura Dean, MD<sup>1</sup>

Created: September 15, 2016.

### Introduction

Capecitabine is a chemotherapy agent that belongs to the drug class of fluoropyrimidines. It is widely used in the treatment of colon cancer, metastatic colorectal cancer, and metastatic breast cancer. Capecitabine is a prodrug that is enzymatically converted to its active form, fluorouracil, which acts as an antimetabolite to slow tumor growth.

The *DPYD* gene encodes dihydropyrimidine dehydrogenase (DPD), an enzyme that catalyzes the rate-limiting step in fluorouracil metabolism. Individuals who are carriers of non-functional *DPYD* variants, such as *DPYD*\*2A, may not be able to metabolize capecitabine at normal rates, and are at risk of potentially life-threatening capecitabine toxicity, such as bone marrow suppression and neurotoxicity. The prevalence of DPD deficiency in Caucasians is approximately 3%-5%.

The FDA-approved drug label for capecitabine states that no capecitabine dose has been proven safe in patients with absent DPD activity, and that there is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test (1).

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing recommendations for fluoropyrimidines (capecitabine, fluorouracil, and tegafur) based on *DPYD* genotype (2) (Table 1). CPIC recommends using an alternative drug for patients who are “poor metabolizers”. These individuals carry two copies of non-functional *DPYD* variants and typically have complete DPD deficiency. CPIC also recommends considering a 50% reduction in starting dose for “intermediate metabolizers”. These individuals carry a combination of a normal-function and a non-functional variant and typically have reduced DPD activity (approximately 50% reduced) (2, 3).

### Drug Class: Fluoropyrimidines

Fluoropyrimidines are a class of antimetabolite drugs that are widely used in the treatment of cancer. Currently, there are three types of fluoropyrimidines in clinical use: capecitabine, fluorouracil, and tegafur. Capecitabine and tegafur are both prodrugs of fluorouracil.

Fluoropyrimidines are thought to exert their chemotherapeutic effects in a number of ways, through several active metabolites. The main mechanism of action is thought to be the inhibition of thymidylate synthase, which plays an important part in the folate-homocysteine cycle, and purine and pyrimidine synthesis pathways. Also, active metabolites can be incorporated into RNA and DNA, ultimately leading to cell death (4).

Approximately 10-40% of patients develop severe and potentially life-threatening toxicity early during treatment with fluoropyrimidines (5). This typically leads to an interruption or discontinuation of potentially effective anticancer therapy, and often requires hospitalization (6).

The inter-individual variation in the occurrence and severity of adverse events in patients receiving fluoropyrimidines can be partly explained by clinical factors, such as age and sex. However, much of the variability in adverse events remains unexplained (7).

Of the genetic factors thought to contribute to fluoropyrimidine intolerance, the *DPYD* gene has been the most studied. This gene encodes the primary enzyme involved in breaking down fluoropyrimidines to inactive metabolites. Individuals who have a deficiency of the DPD enzyme have a significantly increased risk of suffering from severe fluoropyrimidine toxicity, and the stratification of patients on the basis of the *DPYD* genotype may help to prevent such adverse events (8-13)

The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published genetics-based dosing recommendations for fluoropyrimidines based on *DPYD* genotype (Table 1).

**Table 1.** 2013 Recommended dosing of Fluoropyrimidines by DPD phenotype, from Clinical Pharmacogenetics Implementation Consortium (CPIC)

Phenotype	Implications for phenotypic measures	Dosing recommendations	Classification of recommendations <sup>a</sup>
Normal metabolizer	Normal DPD activity and “normal” risk for fluoropyrimidine toxicity	Use label-recommended dosage and administration	Moderate
Intermediate metabolizer	Decreased DPD activity (leukocyte DPD activity at 30–70% that of the normal population) and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs	Start with at least a 50% reduction in starting dose, followed by titration of dose based on toxicity <sup>b</sup> or pharmacokinetic test (if available)	Moderate
Poor metabolizer	Complete DPD deficiency and increased risk for severe or even fatal drug toxicity when treated with fluoropyrimidine drugs	Select alternative drug	Strong

Fluoropyrimidines: 5-fluorouracil, capecitabine, and tegafur.

DPD, dihydropyrimidine dehydrogenase.

<sup>a</sup> Rating scheme is described here (2)

<sup>b</sup> Increase the dose in patients experiencing no or clinically tolerable toxicity to maintain efficacy; decrease the dose in patients who do not tolerate the starting dose to minimize toxicities.

Table is adapted from Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clinical pharmacology and therapeutics*.2013;94(6):640-5 (2)

Note: The nomenclature used in this table reflects the standardized nomenclature for pharmacogenetic terms proposed by CPIC in a 2016 paper, “Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)” (14).

## Drug: Capecitabine

Capecitabine is a form of chemotherapy used as an adjunct treatment for colon cancer, and as either monotherapy or part of combination therapy for metastatic colorectal cancer and metastatic breast cancer (1).

Capecitabine is an orally administered prodrug—it is converted to its active form, fluorouracil, by thymidine phosphorylase—an enzyme that tends to be found in higher concentrations in tumors compared to normal tissue and plasma. Fluorouracil is structurally similar to pyrimidines, and the enzyme that catalyzes the rate-

limiting step in the breakdown of pyrimidines (DPD, dihydropyrimidine dehydrogenase) also catalyzes the rate-limiting step in 5-fluorouracil catabolism. DPD catalyzes the conversion of fluorouracil to the non-cytotoxic dihydrofluorouracil (DHFU) (15).

Symptomatic DPD deficiency is a rare autosomal recessive disorder with a wide range of symptoms, ranging from no symptoms or signs, to severe neurological problems. In affected individuals, the absent or greatly reduced DPD activity results in uracil and thymine accumulating in the blood, urine, and cerebrospinal fluid. Neurological symptoms typically manifest in early childhood and include seizures, small head size, and delayed cognitive and motor development (16).

Symptomatic DPD deficiency is typically caused by homozygous inactivation of *DPYD*; whereas individuals who are heterozygotes tend to be asymptomatic. However, all patients with less than 70% DPD activity are considered at risk for the development of severe drug toxicity when treated with fluoropyrimidines (17). Signs of capecitabine toxicity include severe diarrhea, severe mucositis, neutropenia, hand-foot syndrome, and neurotoxicity (1).

Approximately 3-5% of Caucasians have partial DPD deficiency and 0.2% have complete DPD deficiency (18). Currently, most patients are not screened for DPD deficiency before starting capecitabine therapy (19).

## Gene: *DPYD*

The *DPYD* gene encodes the enzyme dihydropyrimidine dehydrogenase (DPD), which catalyzes the first and the rate-limiting step in the breakdown of the pyrimidine nucleotides thymine and uracil. DPD also catalyzes the rate-limiting step in the breakdown of fluoropyrimidines.

Many *DPYD* variants have been described, although only a few have been demonstrated to influence DPD enzyme activity. *DPYD*\*1 is the wild-type allele and is associated with normal enzyme activity. Individuals who carry two copies of *DPYD* alleles with normal activity are known as “normal metabolizers” and have fully functional DPD enzyme activity (Table 2 and Table 3). Next to *DPYD*\*1, the *DPYD* alleles \*4, \*5, \*6, and \*9A are also considered to have normal activity (20).

**Table 2.** Activity status of selected *DPYD* Alleles

Allele type	Alleles
Functional	*1, *4, *5, *6, *9A
Nonfunctional	*2A, *13, rs67376798

Table is adapted from (12, 15) For the nomenclature of human *DPYD* alleles, please see (21)

The nonfunctional *DPYD* variants which have been associated with low DPD activity and an increased risk of toxicity with fluoropyrimidines include \*2A, \*13, and rs67376798 (15). The most well studied variant is *DPYD*\*2A, in which a single nucleotide substitution at the invariant splice donor site of intron 14 leads to translation skipping exon 14, resulting in the production of a truncated protein with virtually no enzyme activity.

Individuals who carry combinations of normal function, decreased function, and/or no function *DPYD* alleles are known as “intermediate metabolizers”. They have partial DPD deficiency and are at increased risk of capecitabine toxicity. And individuals who carry a combination of nonfunctional *DPYD* alleles and/or decreased function *DPYD* alleles are known as “poor metabolizers”. They have complete DPD deficiency and are at an even higher risk of capecitabine toxicity. Overall, the prevalence of individuals who are heterozygous for nonfunctional variant *DPYD* alleles (partially DPD deficient) that place them at risk of severe drug reactions is estimated to be as high as 3-5%, but this varies in different populations (5, 17, 22-25). For example, in the Dutch population, the *DPYD*\*2A had an allele frequency of 0.91% in Caucasians (17).

**Table 3** Assignment of likely phenotype based on *DPYD* genotypes

Likely phenotype	Functional definition	Genetic definition	Example diplotypes
Normal metabolizer	Fully functional DPD enzyme activity	Combinations of normal function and decreased function alleles	<i>DPYD</i> *1/*1
Intermediate metabolizer (~3–5% of patients)	Decreased DPD enzyme activity (activity between normal and poor metabolizer)	Combinations of normal function, decreased function, and/or no function alleles	*1/*2A; *1/*13; or *1/rs67376798
Poor metabolizer (~0.2% of patients)	Little to no DPD enzyme activity	Combination of no function alleles and/ or decreased function alleles	*2A/*2A; 13/*13; *2/*13; or rs67376798/ rs67376798

Table is adapted from Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clinical pharmacology and therapeutics*.2013;94(6):640-5 (2)

Note: The nomenclature used in this table reflects the standardized nomenclature for pharmacogenetic terms proposed by CPIC in the 2016 paper, “Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)” (14).

A recent study proposed distinguishing between the various *DPYD* alleles and their functionality by assigning gene activity scores. The use of such scores could result in differentiated individualized dosing advice for fluoropyrimidines, which is essential for reducing toxic side effects while maintaining efficacy (12).

## Genetic Testing

The NIH Genetic Testing Registry, GTR, displays genetic tests that are currently available for the *DPYD* gene and the capecitabine drug response. The *DPYD*\*2A variant is the most commonly tested.

Biochemical genetic tests may also be used, which assess the level of activity of the DPD enzyme. These tests include biochemical assays such as analyte testing (e.g., measuring the amount of thymine and uracil in the urine or blood) or an enzyme assay (e.g., directly measuring the activity of DPD using RNA extracted from blood cells and measuring the DPD mRNA copy number) (2, 26, 27).

GTR provides a list of biochemical tests that assess the levels of thymine and uracil analytes, and the activity of the enzyme dihydropyrimidine dehydrogenase.

## Therapeutic Recommendations based on Genotype

**This section contains excerpted<sup>1</sup> information on gene-based dosing recommendations. Neither this section nor other parts of this review contain the complete recommendations from the sources.**

**2016 Statement from the US Food and Drug Administration (FDA):** Based on postmarketing reports, patients with certain homozygous or certain compound heterozygous mutations in the *DPD*<sup>2</sup> gene that result in complete or near complete absence of DPD activity are at increased risk for acute early-onset of toxicity and severe, life-threatening, or fatal adverse reactions caused by capecitabine (e.g., mucositis, diarrhea, neutropenia, and neurotoxicity). Patients with partial DPD activity may also have increased risk of severe, life-threatening, or fatal adverse reactions caused by capecitabine.

Withhold or permanently discontinue capecitabine based on clinical assessment of the onset, duration and severity of the observed toxicities in patients with evidence of acute early-onset or unusually severe toxicity, which may indicate near complete or total absence of DPD activity. No capecitabine dose has been proven safe

<sup>1</sup> The FDA labels specific drug formulations. We have substituted the generic names for any drug labels in this excerpt. The FDA may not have labeled all formulations containing the generic drug.

<sup>2</sup> Note: the official gene symbol is *DYPD*. *DPD* is an alternate gene symbol.

for patients with complete absence of DPD activity. There is insufficient data to recommend a specific dose in patients with partial DPD activity as measured by any specific test.

**Please review the complete therapeutic recommendations that are located here: (1).**

**2013 Statement from the Clinical Pharmacogenetics Implementation Consortium (CPIC):** [...] Furthermore, patients who are heterozygous for the nonfunctional *DPYD* variants mostly demonstrate partial DPD deficiency (leukocyte DPD activity at 30–70% that of the normal population). Thus, our recommendation is to start with at least a 50% reduction of the starting dose; followed by an increase in dose in patients experiencing no or clinically tolerable toxicity, to maintain efficacy; and a decrease in dose in patients who do not tolerate the starting dose, to minimize toxicities. An alternative is pharmacokinetic-guided dose adjustment (if available). Patients who are homozygous for *DPYD*\*2A, \*13, or rs67376798 may demonstrate complete DPD deficiency, and the use of 5-fluorouracil or capecitabine is not recommended in these patients. Because capecitabine and tegafur are converted to 5-fluorouracil and then metabolized by DPD, the clearance of and exposure to 5-fluorouracil, in addition to its toxic effects, are similar in patients with these variants.

**Please review the complete therapeutic recommendations that are located here: (2).**

## Nomenclature

Common allele name	Alternative names	HGVS reference sequence		dbSNP reference identifier for allele location
		Coding	Protein	
<i>DPYD</i> *2A	IVS14+1G>A c.1905+1G>A	NM_000110.3:c.1905+1G>A	Not applicable—deletion of exon 14 leads to the production of a truncated protein	rs3918290
<i>DPYD</i> *13	1679T>G Ile560Ser	NM_000110.3:c.1679T>G	NP_000101.2:p.Ile560Ser	rs55886062
rs67376798	2846A>T Asp949Val	NM_000110.3:c.2846A>T	NP_000101.2:p.Asp949Val	rs67376798

Guidelines for the description and nomenclature of gene variations are available from the Human Genome Variation Society (HGVS): <http://www.hgvs.org/content/guidelines>

## Acknowledgments

The author would like to thank Linda Henricks, PharmD, and Professor Jan HM Schellens, MD PhD, The Netherlands Cancer Institute, Amsterdam, NL; Mohamed Nagy, Clinical Pharmacist, Head of the Personalised Medication Management Unit, Department of Pharmaceutical Services, Children's Cancer Hospital, Egypt; and Emily K. Pauli, Director of Research, Clearview Cancer Institute, Alabama; for reviewing this summary.

## References

1. CAPECITABINE- capecitabine tablet, film coated [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; 2016. Available from: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03dd3301-e9ce-40af-84e1-7b70fc6557b0>
2. Caudle K.E., Thorn C.F., Klein T.E., Swen J.J., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. *Clin Pharmacol Ther.* 2013;94(6):640–5. PubMed PMID: 23988873.
3. PharmGKB [Internet]. Palo Alto (CA): Stanford University. Chemical: Prodrug - capecitabine. Clinical PGx - Dosing Guidelines. [Cited 2016 June 27]. Available from: <https://www.pharmgkb.org/molecule/PA448771-tabview=tab0&subtab=31>

4. Wilson P.M., Danenberg P.V., Johnston P.G., Lenz H.J., et al. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. *Nat Rev Clin Oncol.* 2014;11(5):282–98. PubMed PMID: 24732946.
5. Amstutz U., Farese S., Aebi S., Largiader C.R. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. *Pharmacogenomics.* 2009;10(6):931–44. PubMed PMID: 19530960.
6. Deenen M.J., Meulendijks D., Cats A., Sechterberger M.K., et al. Upfront Genotyping of DPYD\*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. *J Clin Oncol.* 2016;34(3):227–34. PubMed PMID: 26573078.
7. Boige V., Vincent M., Alexandre P., Tejpar S., et al. DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. *JAMA Oncol.* 2016. PubMed PMID: 26794347.
8. Raida, M., W. Schwabe, P. Hausler, A.B. Van Kuilenburg, et al., *Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.* *Clinical cancer research : an official journal of the American Association for Cancer Research,* 2001. 7(9): p. 2832-9.
9. Del Re M., Michelucci A., Di Leo A., Cantore M., et al. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. *EPMA J.* 2015;6(1):17. PubMed PMID: 26330892.
10. Lee A.M., Shi Q., Pavay E., Alberts S.R., et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). *J Natl Cancer Inst.* 2014;106(12) PubMed PMID: 25381393.
11. Gentile G., Botticelli A., Lionetto L., Mazzuca F., et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. *Pharmacogenomics J.* 2015. PubMed PMID: 26216193.
12. Henricks L.M., Lunenburg C.A., Meulendijks D., Gelderblom H., et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. *Pharmacogenomics.* 2015;16(11):1277–86. PubMed PMID: 26265346.
13. Toffoli G., Giodini L., Buonadonna A., Berretta M., et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. *Int J Cancer.* 2015;137(12):2971–80. PubMed PMID: 26099996.
14. Caudle K.E., Dunnenberger H.M., Freimuth R.R., Peterson J.F., et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). *Genet Med.* 2016. PubMed PMID: 27441996.
15. Deenen, M.J., J. Tol, A.M. Burylo, V.D. Doodeman, et al., *Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.* *Clinical cancer research : an official journal of the American Association for Cancer Research,* 2011. 17(10): p. 3455-68.
16. Al-Sanna'a N.A., Van Kuilenburg A.B., Atrak T.M., Abdul-Jabbar M.A., et al. Dihydropyrimidine dehydrogenase deficiency presenting at birth. *Journal of inherited metabolic disease.* 2005;28(5):793–6. PubMed PMID: 16151913.
17. Van Kuilenburg A.B., Vreken P., Abeling N.G., Bakker H.D., et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. *Human genetics.* 1999;104(1):1–9. PubMed PMID: 10071185.
18. Morel A., Boisdron-Celle M., Fey L., Soulie P., et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. *Mol Cancer Ther.* 2006;5(11):2895–904. PubMed PMID: 17121937.
19. Thomas F., Hennebelle I., Delmas C., Lochon I., et al. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. *Clin Pharmacol Ther.* 2016;99(2):235–42. PubMed PMID: 26265035.



20. Offer S.M., Fossum C.C., Wegner N.J., Stuflesser A.J., et al. Comparative functional analysis of *DPYD* variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. *Cancer Res.* 2014;74(9):2545–54. PubMed PMID: 24648345.
21. McLeod H.L., Collie-Duguid E.S., Vreken P., Johnson M.R., et al. Nomenclature for human *DPYD* alleles. *Pharmacogenetics.* 1998;8(6):455–9. PubMed PMID: 9918128.
22. Saif M.W., Ezzeldin H., Vance K., Sellers S., et al. *DPYD*\*2A mutation: the most common mutation associated with DPD deficiency. *Cancer chemotherapy and pharmacology.* 2007;60(4):503–7. PubMed PMID: 17165084.
23. Morel A., Boisdron-Celle M., Fey L., Soulie P., et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. *Molecular cancer therapeutics.* 2006;5(11):2895–904. PubMed PMID: 17121937.
24. Gonzalez F.J., Fernandez-Salguero P. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase deficiency. *Trends in pharmacological sciences.* 1995;16(10):325–7. PubMed PMID: 7491709.
25. Lee, A., H. Ezzeldin, J. Fourie, and R. Diasio, *Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.* *Clinical advances in hematology & oncology : H&O,* 2004. 2(8): p. 527-32.
26. van Staveren M.C., Guchelaar H.J., van Kuilenburg A.B., Gelderblom H., et al. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. *Pharmacogenomics J.* 2013;13(5):389–95. PubMed PMID: 23856855.
27. Meulendijks D., Cats A., Beijnen J.H., Schellens J.H. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice? *Cancer Treat Rev.* 2016;50:23–34. PubMed PMID: 27589829.

## License

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.